Malignant Melanoma: Update Bulletin [April 2016]
Gain new KOL insights on the latest events happening in Malignant melanoma (MM): expanded indication label for Bristol-Myers Squibb’s Opdivo plus Yervoy regimen for metastatic melanoma patients regardless of BRAF status; Philogen’s pivotal Phase III trials for Darleukin and Fibromun in patients with stage IIIB/C melanoma and the prospects of Provectus Biopharmaceuticals’ PV-10 in Phase III trial are also discussed.
- Will Opdivo plus Yervoy combination therapy use increase significantly following BRAF V600 (wild-type & mutation-positive) label expansion?
- Which patient subsets do KOLs think will benefit most from Opdivo plus Yervoy combination?
- What are KOLs expecting from the two year survival data in CheckMate 069?
- How successful do KOLs think Philogen’s Darleukin and Fibromun immunocytokines will be in melanoma?
- What safety concerns do KOLs have with Darleukin/Fibromun and which combinations could hold the key to their success?
- What are the prospects of Provectus’ PV-10 and how do KOLs view the inclusion of Imlygic as a comparator in Phase III study?
